The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats

被引:9
|
作者
Nowak, Beata [1 ]
Matuszewska, Agnieszka [1 ]
Filipiak, Jaroslaw [2 ]
Nikodem, Anna [2 ]
Merwid-Lad, Anna [1 ]
Piesniewska, Malgorzata [1 ]
Fereniec-Golebiewska, Lidia [1 ]
Kwiatkowska, Joanna [1 ]
Szelag, Adam [1 ]
机构
[1] Wroclaw Med Univ, Dept Pharmacol, Ul J Mikulicza Radeckiego 2, PL-50345 Wroclaw, Poland
[2] Wroclaw Univ Technol, Div Biomed Engn & Expt Mech, Wroclaw, Poland
来源
ADVANCES IN MEDICAL SCIENCES | 2016年 / 61卷 / 01期
关键词
Bone turnover; Retinoid receptor X (RXR); Retinoid acid receptor (RAR); Stress yield; VITAMIN-A; OVARIECTOMIZED RATS; IN-VITRO; PHARMACOKINETICS; DIFFERENTIATION; EXPRESSION; RESORPTION; FRACTURE; PATHWAY; HEALTH;
D O I
10.1016/j.advms.2015.09.001
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Purpose: The purpose of this study was to investigate the influence of selective agonists of the retinoid receptor X (RXR) and the retinoid acid receptor (RAR) on bone metabolism in rats. Methods: Thirty six male Wistar rats were divided into three groups: receiving bexarotene, or tazarotene, or to control group. Serum biochemical markers of bone turnover (osteocalcin - OC, tartrate resistant acid phosphatase 5 - TRACP5b and osteoprotegerin - OPG) and mechanical properties of bones were analyzed. Results: There was a significant decrease in the femur index value in groups receiving tazarotene and bexarotene on Day 14 (8% and 20% respectively, p = 0.0039). On Day 28, 14 days after discontinuation of tazarotene and bexarotene, the difference in femur indexes was still significant (4% for T1-6 and B1-6, p = 0.0270). In the bexarotene group an increase in mean plasma osteocalcin level and mean plasma TRACP5b level was detected. In the tazarotene group the mean osteocalcin level remained unchanged and the mean plasma TRACP5b level decreased. An increased yield stress was detected in groups receiving retinoids comparing to controls after 14 days of tazarotene and bexarotene administration. Conclusion: Although bexarotene and tazarotene administration caused decrease in the femur index, mechanisms responsible for that effect seem to be different. Our results suggest that bexaroten increases bone turnover. On the contrary, tazaroten seems to have inhibitory effect on bone turnover. A counter influence of selective RAR and RXR agonists on the bone turnover might be the reason for inconsistency in results from published research concerning the influence of retinoids on bone metabolism. (C) 2015 Medical University of Bialystok. Published by Elsevier Sp. z o.o. All rights reserved.
引用
收藏
页码:85 / 89
页数:5
相关论文
共 50 条
  • [1] Influence of selective agonists of retinoid receptor X (RXR) and retinoid acid receptor (RAR) on bone metabolism in rats
    Beata Nowak
    Agnieszka Matuszewska
    Anna Merwid-Ląd
    Małgorzata Pieśniewska
    Lidia Fereniec-Gołębiewska
    Joanna Kwiatkowska
    Adam Szeląg
    Pharmacological Reports, 2013, 65 (Suppl 1) : 71 - 71
  • [2] Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
    Qi, Lisi
    Guo, Yuanyuan
    Zhang, Pei
    Cao, Xiaorong
    Luan, Yuxia
    CURRENT DRUG METABOLISM, 2016, 17 (02) : 118 - 128
  • [3] Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat
    Liu, S
    Ogilvie, KM
    Klausing, K
    Lawson, MA
    Jolley, D
    Li, DM
    Bilakovics, J
    Pascual, B
    Hein, N
    Urcan, M
    Leibowitz, MD
    ENDOCRINOLOGY, 2002, 143 (08) : 2880 - 2885
  • [4] A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
    W-C Yen
    R Y Prudente
    M R Corpuz
    A Negro-Vilar
    W W Lamph
    British Journal of Cancer, 2006, 94 : 654 - 660
  • [5] Teratogenicity and Fetal-Transfer Assessment of the Retinoid X Receptor Agonist Bexarotene
    Takamura, Yuta
    Kato, Izumi
    Fujita-Takahashi, Manami
    Azuma-Nishii, Midori
    Watanabe, Masaki
    Nozaki, Rui
    Akehi, Masaru
    Sasaki, Takanori
    Hirano, Hiroyuki
    Kakuta, Hiroki
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2022, 5 (09) : 811 - 818
  • [6] A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
    Yen, WC
    Prudente, RY
    Corpuz, MR
    Negro-Vilar, A
    Lamph, WW
    BRITISH JOURNAL OF CANCER, 2006, 94 (05) : 654 - 660
  • [7] Chemoprevention of small cell lung carcinomas in mice by the retinoid X receptor agonist bexarotene
    Wang, Yian
    Wen, Weidong
    Yi, Yijun
    Zhang, Zhongqiu
    Lubet, Ronald A.
    You, Ming
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [8] Potential role of a selective retinoid receptor agonist bexarotene (LGD1069) in the treatment of advanced, metastatic NSCLC
    Dziewanowska, ZE
    Negro-Vilar, A
    Mabry, M
    Hermann, T
    Lamph, WW
    Bissonnette, RP
    Loewen, G
    PROCEEDINGS OF THE 9TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2004, : 121 - 124
  • [9] Potential role of a selective retinoid receptor agonist bexarotene (LGD1069) in the treatment of advanced, metastatic NSCLC
    Dziewanowska, ZE
    Negro-Vilar, A
    Mabry, M
    Lamph, W
    Bissonnette, R
    Loewen, G
    LUNG CANCER, 2004, 45 : S80 - S80
  • [10] The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma
    Yen, WC
    Lamph, WW
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) : 824 - 834